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tion and increased intrahepatic vasoconstriction are the rel-
evant pathophysiological pathways. Thromboxane A 2 and 
leukotriene (LT) C 4 /D 4 have been identified as important va-
soconstrictors. Accordingly, treatment with montelukast to 
inhibit the cysteinyl-LT 1 receptor reduced portal pressure in 
cirrhotic rat livers. Clinical studies have demonstrated that 
activation of KCs, estimated by the amount of soluble CD163 
in the blood, correlates with the risk for variceal bleeding. 
Additionally, intestinal decontamination with rifaximin in 
patients with alcohol-associated liver cirrhosis reduced the 
portal pressure and the risk for variceal bleeding.  Conclu-
sions: TLR activation of nonparenchymal liver cells by patho-
gens results in portal hypertension. This might explain the 
pathophysiologic correlation between microbial infections 
and portal hypertension in patients with liver cirrhosis. These 
findings are the basis for both better risk stratifying and new 
treatment options, such as specific inhibition of TLR for pa-
tients with liver cirrhosis and portal hypertension. 
 © 2015 S. Karger AG, Basel 
 Infections in Patients with Liver Cirrhosis 
 Bacterial infections are a relevant problem in patients 
with liver cirrhosis. One meta-analysis showed a risk for 
mortality up to 4-fold for patients with liver cirrhosis suf-
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 Abstract 
 Background: Microbial infections are a relevant problem for 
patients with liver cirrhosis. Different types of bacteria are 
responsible for different kinds of infections:  Escherichia coli 
and  Klebsiella pneumoniae are frequently observed in spon-
taneous bacterial peritonitis or urinary tract infections, and 
 Streptococcus pneumoniae and  Mycoplasma pneumoniae in 
pulmonary infections. Mortality is up to 4-fold higher in in-
fected patients with liver cirrhosis than in patients without 
infections.  Key Messages: Infections in patients with liver cir-
rhosis are due to three major reasons: bacterial transloca-
tion, immune deficiency and an increased incidence of sys-
temic infections. Nonparenchymal liver cells like Kupffer 
cells, sinusoidal endothelial cells and hepatic stellate cells 
are the first liver cells to come into contact with microbial 
products when systemic infection or bacterial translocation 
occurs. Kupffer cell (KC) activation by Toll-like receptor (TLR) 
agonists and endothelial sinusoidal dysfunction have been 
shown to be important mechanisms increasing portal pres-
sure following intraperitoneal lipopolysaccharide pretreat-
ment in cirrhotic rat livers. Reduced intrahepatic vasodila-
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fering from infection  [1] . Different kinds of infections are 
relevant in patients with liver cirrhosis: spontaneous bac-
terial peritonitis (SBP), urinary tract infections and pul-
monary infections. Common pathogens for SBP are  Esch-
erichia coli ,  Klebsiella pneumoniae ,  Pseudomonas aerugi-
nosa and  Streptococcus pneumoniae ; for urinary tract 
infections  E. coli and  K. pneumoniae , and fur pulmonary 
infections  S. pneumoniae and  Mycoplasma pneumoniae 
are frequently involved (see  table 1 ). There are three rel-
evant reasons why patients with liver cirrhosis suffer 
more often from infections: bacterial translocation, im-
mune deficiency and an increased incidence of systemic 
infections, as presented by the three columns in  figure 1 . 
 Bacterial Translocation 
 Bacterial translocation is supposed to be a common 
problem in patients with liver cirrhosis. Three main 
mechanisms influence bacterial translocation: the intes-
tinal microbiome, the intestinal barrier and the intestinal 
lymphatic tissue. The intestinal microbiome is altered in 
patients with liver cirrhosis due to malnutrition, bile acid 
deficiency, potential alcohol consumption and an in-
creasing number of multiresistant bacteria. Additionally, 
the intestinal barrier is altered in patients with liver cir-
rhosis. Alterations are due to potential alcohol ingestion 
and proinflammatory cytokines, e.g. TNF-α. Via the in-
testinal lymphatic tissue a relevant amount of microbial 
products reaches the portal vein in patients with liver cir-
rhosis. This amount of microbial products is higher in 
patients with liver cirrhosis compared to healthy volun-
teers  [2–4] . Impaired clearance of the lymphatic tissue 
aggravates bacterial translocation. The microbial prod-
ucts from the intestinal tract reach the sinusoidal lumen 
and first meet the nonparenchymal liver cells, like Kupffer 
cells (KCs), sinusoidal endothelial cells (SECs), hepatic 
stellate cells (HSCs) and migrated dendritic cells (DCs; 
 fig. 2 ).
 Table 1.  Frequent kinds of infections and common pathogens in 
patients with liver cirrhosis





Urinary tract infections E. coli
K. pneumoniae
































 Fig. 1. The three columns represent the most common reasons for 
infections in patients with liver cirrhosis. Patients with liver cir-
rhosis often suffer from bacterial infections. One postulated mech-
anism is bacterial translocation due to reduced bowel motility and 
increased intestinal permeability. Furthermore, patients with liver 
cirrhosis have immune deficiency, and the incidence of systemic 




















 Fig. 2. Sinusoidal architecture of the liver. Blood flow from the 
portal vein enriches the sinusoidal compartments of the liver. On 
the forefront of the sinusoidal lumen there are KCs and SECs. They 
are embedded in the HSCs, which have the potential for contrac-
tion because they have myosin and actin filaments. Also, some 
migrated DCs can be found in the layer of nonparenchymal cells, 
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 Portal Hypertension 
 The pathophysiology of portal hypertension underlies 
a wide range of different mechanisms. However, there are 
two major mechanisms: increased splanchnic blood flow 
and increased intrahepatic resistance. The intrahepatic 
resistance is influenced by the altered liver architecture 
(cirrhotic nodules and scars) and by the intrahepatic con-
traction. Intrahepatic contraction is dependent on both 
the production of and response to vasoconstrictors and 
vasodilators. In cirrhotic livers the production of and re-
sponse to vasoconstrictors is increased. The production 
of and response to vasodilators, however, is diminished. 
Therefore, the intrahepatic contraction is a dynamic 
component and might be targeted by pharmacologic 
treatment.
 Infections and Portal Hypertension 
 The current concept of the interaction between infec-
tions and the liver is as follows. There is a preexisting mi-
crobial infection in patients with liver cirrhosis meaning 
pathogens are present in the systemic circulation. Patho-
gens are detected by receptors on liver cells, e.g. Toll-like 
receptors (TLRs). A reaction in the liver will occur de-
pending on the stimulation profile. Cytokine release, va-
soconstriction due to an increased production of vaso-
constrictors and altered vasodilatation lead to an in-
creased risk for complications of liver cirrhosis, such as 
variceal bleeding, impairment of renal function, hepatic 
encephalopathy and systemic inflammatory response 
( fig. 3 ). Experimental data has shown that 24-hour treat-
ment with lipopolysaccharide (LPS) in cirrhotic rats in-
duced liver sinusoidal endothelial dysfunction. This was 
shown by a decreased  vasodilatory response to acetylcho-
line and a decreased endothelial NOS phosphorylation 
following LPS pretreatment. The inhibition of inducible 
NOS prevented liver endothelial dysfunction  [5] . In an-
other study, LPS-induced intrahepatic endothelial dys-
function was prevented by simvastatin treatment, indi-
cating that statins might be a treatment option for liver 
protection during endotoxemia  [6] .
 Experimental data has also focused on vasoconstric-
tors . Different vasoconstrictors are metabolites of the ar-
achidonic acid pathway. Arachidonic acid is metabolized 
to prostaglandin (PG) G 2 by cyclooxygenase and to 
5-HPETE by 5-lipoxygenase. PGG 2 is further degraded to 
PGH 2 , thromboxane (TX) A 2 and its stable degradation 
product TXB 2 , and on the other side to PGD 2 , E 2 , F 2 and 
I 2 . 5-HPETE is degraded to leukotriene (LT) A 4 and con-
secutively to B 4 or the cysteinyl (Cys)-LT C 4 , D 4 and E 4 . 
In the cirrhotic liver the vasoconstrictor TXA 2 and Cys-
LT C 4 and D 4 have been identified as the most relevant 
 [7–17] .
 KC Activation in Cirrhotic Rat Livers 
 KCs can be activated by TLRs  [18, 19] . Zymosan is 
supposed to activate TLR2 and TLR6. The acute admin-
istration of zymosan in the isolated liver perfusion system 
increased portal perfusion pressure by about 3-fold. This 
increase could be reduced by additional indomethacin 
administration  [11] . In cirrhotic rat livers portal perfu-
sion pressure increased impressively following infusion 
of zymosan; however, most interestingly, intraperitoneal 
pretreatment with LPS enhanced this increase of portal 
perfusion pressure to a higher degree  [12] . Additional 
gadolinium chloride pretreatment for the blockade of 
KCs reduced LPS/zymosan-induced increase of portal 
perfusion pressure  [12] . This indicates that KCs are im-
portant players in the TLR-mediated increase of portal 
perfusion pressure. In parallel with portal hypertension, 
TXB 2 and Cys-LT efflux into the effluent perfusate in-
creased  [12] . In further studies the effect of portal perfu-
sion pressure increase following TXA 2 analogon infusion 
Preexisting bacterial infection 
in patients with liver cirrhosis
Increased risk:
- Variceal bleeding
- Impairment of renal function
- Hepatic encephalopathy 
- Systemic inflammatory response 
Presence of bacterial products in the circulation
Detection by the liver
Reaction depending on stimulation profile
Cytokine release, vasoconstriction, 
altered vasodilation
 Fig. 3. Proposed pathophysiology for an increased risk of compli-
cations in patients with liver cirrhosis. Bacterial products from the 
systemic circulation reach the liver and are detected there. A reac-
tion depending on the stimulation profile is then generated. The 
following cytokine release resulting in vasoconstriction and al-
tered vasodilation increases the risk for variceal bleeding, impair-
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was enhanced by additional infusion of LTC 4  [13] . This 
indicates that both arachidonic acid metabolites act inde-
pendently and additively. While TXA 2 inhibition would 
influence thrombocyte aggregation, LT inhibition pre-
sumably has no obvious effects for patients with liver cir-
rhosis. Inhibition of Cys-LT 1 receptor might therefore be 
a reasonable therapeutic strategy for patients with portal 
hypertension; experimental data ruled out the beneficial 
effect of Cys-LT 1 receptor inhibition with montelukast in 
rat liver cirrhosis ( fig. 4 )  [13] .
 A further therapeutic approach investigated in experi-
mental studies might be the administration of rifaximin 
for intestinal decontamination. It has been shown that 
pretreatment with rifaximin reduced portal pressure in 
mice with bile duct ligation (BDL)-induced liver cirrhosis 
 [20] . It has also been shown that the TLR4-dependent 
cross-talk between stellate cells and endothelial cells was 
inhibited in mice with liver fibrosis  [20] .
 Therefore, KCs seem to play an important role in TLR-
mediated production of vasoconstrictors and the associ-
ated increase of portal pressure. The effector cells of in-
trahepatic contraction are presumably the HSCs. Rele-
vant mechanisms of intrahepatic contraction Rho kinases 
have been evaluated  [13, 14, 21–25] . The importance of 
Rho kinase for HSC contraction was first described by 
studies with isolated cultured HSCs. During their activa-
tion and transformation to the myofibroblastic pheno-
type, HSCs acquire contractile potential. Such studies 
 investigated how Rho kinase affects the resting tone of 
HSCs and vasoconstrictor-induced HSC contractions. 
Under resting conditions, the Rho kinase inhibitors 
Y27632 and HA1077 relaxed rat HSCs in collagen matrix 
assay  [26, 27] . HSC activation is associated with excessive 
proliferation and transformation to the contractile phe-
notype  [28] , which confers hypercontractility to the in-
trahepatic vasculature resulting in increased intrahepatic 
vascular resistance  [21] . HSC-specific blockade of Rho 
kinases might therefore be another promising therapeu-
tic strategy in TLR-dependent portal hypertension  [24] .
 Immune Deficiency 
 Beside TLR-mediated intrahepatic contraction due to 
bacterial translocation and due to an increased risk for 
bacterial infections, immune deficiency plays an impor-
tant role in patients with liver cirrhosis. Different mecha-
nisms underlie the pathophysiology of immune deficien-
cy in cirrhosis, including the deficiency of bactericidal 
and opsonic activities  [29] , altered monocyte function 
and defective chemotaxis  [1, 2] . Furthermore, PGE 2 has 
been shown to be an important mediator of immunosup-
pression in liver cirrhosis  [30] . Increased PGE 2 levels 
have been found in plasma of patients with liver cirrhosis 
and acute decompensation of liver function  [30] . Macro-
phages exhibited reduced bacterial killing when incubat-
ed with plasma from patients with acutely decompensat-
ed cirrhosis. This effect was reversed by additional treat-
ment of the macrophages with an antagonist to prostanoid 
E receptors 1–3 and prostanoid D 2 receptor. Further-
more, mice with BDL-induced cirrhosis were injected 
with group B streptococcus intraperitoneally. Bacterial 
load in the peripheral blood was elevated in BDL animals 













 Fig. 4. Proposed pathophysiology of KC ac-
tivation and portal pressure increase. Ago-
nists of TLRs, e.g. different pathogens dur-
ing systemic infections or in the context of 
bacterial translocation, activate KCs, which 
increases TXA 2 /B 2 production and LT C 4 /
D 4 production via cyclooxygenase and TX 
synthase or 5-lipoxygenase. The activation 
of HSCs via the TX receptor or the Cys-LT 1 
receptor presumably leads to a contraction 
of HSCs and, therefore, an increase in por-
tal pressure. Vice versa blockade of KCs by 
gadolinium chloride or blockade of the 
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by indomethacin treatment. Indomethacin treatment 
also improved survival in BDL animals. Furthermore, the 
authors gave a potential treatment option. Treatment 
with albumin (20%) resulted in lower levels of blood bac-
teria in BDL animals exposed to bacteria. In parallel, low-
er levels of PGE 2 have been measured. The authors there-
fore hypothesized that PGE 2 is an important mediator of 
immunosuppression in liver cirrhosis and this effect 
could be attenuated by albumin treatment  [30] .
 Clinical Studies 
 In accordance with the pathophysiological data, there 
is substantial evidence in clinical studies that the immedi-
ate administration of antibiotics is essential in patients 
with variceal bleeding  [31–35] . Antibiotics should be ad-
ministered together with vasoactive drugs before endo-
scopic therapy when the event of variceal bleeding is sus-
pected or obvious. The earlier the pharmacological treat-
ment starts, the better for the patient. The choice of the 
antibiotic therapy is dependent on the local resistance 
spectrum. A recent study investigated the different effects 
of different vasoactive drugs. It has been demonstrated 
that hemostatic effects and safety did not differ signifi-
cantly between terlipressin, somatostatin and octreotide 
as adjuvants to endoscopic treatment in patients with 
acute gastroesophageal variceal bleeding  [36] . 
 Furthermore, new markers haven been evaluated in 
clinical studies in the context of infection as a trigger for 
portal hypertension. One of these markers is soluble (s)
CD163. sCD163 can be measured in the peripheral blood 
via ELISA and is supposed to indicate KC activation. In-
terestingly, the cumulative bleeding hazard correlated 
with the level of sCD163  [37] . sCD163 might therefore be 
a new clinical tool for patients with portal hypertension 
to better predict the risk of variceal bleeding. Rifaximin 
has been tested in patients with alcoholic cirrhosis as a 
new therapeutic strategy. It was presumed that portal hy-
pertension was attenuated by intestinal decontamination. 
Indeed, the hepatic venous pressure gradient decreased 
after 4 weeks of rifaximin treatment  [38] . A second study 
showed that patients under treatment with rifaximin 
more rarely suffered from variceal bleeding compared to 
a control group  [39] . 
 To better understand the mechanisms and the rele-
vance of bacterial translocation in liver cirrhosis, blood 
from the portal vein might be very helpful. However, 
there are several limitations to obtaining blood from the 
portal vein. Some studies have investigated blood samples 
taken during transjugular intrahepatic portosystemic 
shunt (TIPS) procedures, comparing blood samples from 
the hepatic vein and the portal vein. In one study it was 
found that cirrhotic livers retain the capacity for clear-
ance of bacterial endotoxin from the portal venous blood 
and that TIPS implantation attenuates this clearance  [40] . 
In this study, LPS-binding protein was measured by lim-
ulus amebocyte lysate assay  [41] . In another study bacte-
rial DNA was measured in blood from the hepatic vein 
and the portal vein during a TIPS procedure  [42] . No 
transhepatic gradient of bacterial DNA was observed. 
The authors concluded that no major hepatic elimination 
of bacterial DNA occurs in advanced liver diseases. Fur-
thermore, the authors demonstrated that bacterial DNA 
was unrelated to a panel of markers of inflammation and 
without relation to portal pressure  [42] . These divergent 
results underline the difficulty in investigating and better 
understanding the mechanisms and consequences of bac-
terial translocation in liver cirrhosis.
 Another clinical study investigated the role of nonse-
lective β-blockers to better understand the pathophysiol-
ogy and as a possible treatment option to reduce bacte-
rial translocation. Nonselective β-blockers are primarily 
known to reduce portal pressure by reducing portal in-
flow. Otherwise, they have also been investigated in more 
detail under the rationale of reducing bacterial transloca-
tion  [43] . The permeability index correlated with the he-
patic venous pressure gradient and, under β-blocker ther-
apy, not only was the hepatic venous pressure gradient 
decreased, but so too was intestinal permeability. Abnor-
mal gastroduodenal permeability and intestinal perme-
ability was associated with a reduced risk for variceal 
bleeding, but no effect on mortality has been observed 
 [43] .
 Another important issue in considering bacterial 
translocation in cirrhotic patients is to take into account 
the use of proton pump inhibitors. There are different 
data on proton pump inhibitors and the risk for develop-
ment of SBP  [44–46] . A recent study found that proton 
pump inhibitors were more frequently used in SBP pa-
tients than in controls, but did not influence the progno-
sis in SBP  [47] . In addition, overuse of proton pump in-
hibitors was encountered in one third of cirrhotic pa-
tients  [47] . It is unclear whether proton pump inhibitors 
increase the risk for spontaneous bacterial infection; 
however, the indication for proton pump inhibitor ther-
apy should be made very thoroughly, in particular in pa-
tients with liver cirrhosis.
 In the context of bacterial translocation and portal hy-
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tients with liver cirrhosis. Probiotics are live microorgan-
isms that produce a beneficial effect to the host when ad-
ministered in an adequate dose. Probiotics are not drugs, 
but rather combinations of bacteria. In adjunctive thera-
py a beneficial effect has been observed in patients receiv-
ing propranolol and in addition VSL#3 as a probiotic 
therapy, with response rates to propranolol being subse-
quently improved  [48] . On the other hand, probiotic ad-
ministration alone did not show effects on portal pressure 
in compensated  [49] and decompensated cirrhosis  [50] .
 Summary and Perspectives 
 The issue of bacterial infections in patients with liver 
cirrhosis and in particular for portal hypertension is a rel-
evant problem and has been focused on even more during 
recent years. In addition to the existing data in humans 
and in animals, further research is essential. In particular, 
research is needed to distinguish between the relevance of 
bacterial translocation and systemic infections like uri-
nary tract infections and pulmonary infections. Non-
parenchymal liver cells might potentially be used for risk 
profiling in future studies and defined cytokine profiles 
might help to better understand the pathophysiology and 
also help to detect risk constellations earlier. Antibiotic 
therapy, especially continuous antibiotic therapy, brings 
the risk of development of resistant bacteria. The forma-
tion of an increasing number of resistant bacteria has 
been observed during recent years. Therefore, a strong 
selection of patients is needed who will in particular prof-
it from continuous antibiotic prophylaxis (e.g. for spon-
taneous bacterial infections). This means a better risk 
stratification is important. Furthermore, precise antibi-
otic therapy for identified constellations has to be consid-
ered in the future, for which profiling and better diagnos-
tic tools might be helpful. Furthermore, the development 
and testing of new therapeutic agents for the treatment of 
patients with liver cirrhosis in the future is essential. In-
hibitors of the 5-lipoxygenase pathway or inhibition of its 
metabolites and development and testing of TLR antago-
nists or specific TLR blocking agents will be necessary to 
improve treatment for patients with liver cirrhosis and 
portal hypertension in the future.
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